Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Reports 163 Percent Jump in Q2 Sales; Raises Full-Year Guidance

NEW YORK (GenomeWeb News) - Illumina yesterday reported a 163-percent surge in second-quarter revenues and swung into profitability from a loss in the second quarter of 2005.
Total receipts for the three months ended July 2 increased to $41.6 million from $15.8 million in the same quarter one year ago.
Illumina posted net income of $6.8 million, compared to a net loss of $15.8 million in the year-ago period. The company noted that its Q2 2005 results included a $15.8 million R&D expense related to its acquisition of CyVera in April 2005.
Research and development expenses rose 17.8 percent to $8.6 million, compared to $7.3 million in the second quarter of 2005.
Illumina also updated its guidance for the third quarter and for the rest of the year. For the third quarter, the company now expects total revenue to be between $44 million and $48 million, or increases of between 126 percent and 146 percent.
For the full year, Illumina said it believes total revenue will be between be between $160 million and $170 million, or increases of between 118 percent and 131 percent year over year.
As of July 2, Illumina had $156.8 million in cash and short-term investments.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.